Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 119 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... October 8, 2025 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 Answers to Your Questions About the COVID-19 Vaccine March 4, 2021 11 top tips for cutting back on alcohol January 13, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up Summer Sun Safety Tips Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas
